This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.

The treatments, which target buildup of amyloid plaques in the brain, appear to be more effective when started earlier in the disease course. However, their use has been limited by coverage restrictions, costs and the challenges of identifying and monitoring eligible patients, among other factors.

New Schaeffer Center modeling estimates that the Alzheimer's treatment donanemab (marketed as Kisunla) could extend life expectancy and time spent living independently, with value accruing to patients, care partners and society more broadly. The estimated value would increase by one-third if treatment were started two years earlier.

"New therapies and diagnostic tools are making it possible to alter the course of Alzheimer's disease, but they come with considerable costs. Our research suggests that investments in early detection could help ensure that patients start treatments when they're more likely to provide the greatest benefit to patients and society," said lead author Jack Chapel, a USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy.

Alzheimer's and related dementias will cost the United States an estimated $818 billion in 2026 , and the economic impact is expected to grow as the population ages.

Source link